Similar articles

• Gender, ethnicity, and genes in cardiovascular disease. Part 2: implications for pharmacotherapy.

  Schaefer BM, Caracciolo V, Frishman WH, Charney P. Schaefer BM, et al. Heart Dis. 2003 May-Jun;5(3):202-14. doi: 10.1097/01.HDX.0000074437.07268.00. Heart Dis. 2003. PMID: 12783634 Review.
• [Secondary prevention of coronary heart disease. How effective are modern therapy methods?].

  Kolenda KD. Kolenda KD. Dtsch Med Wochenschr. 2003 Sep 5;128(36):1849-53. doi: 10.1055/s-2003-41970. Dtsch Med Wochenschr. 2003. PMID: 12964107 Review. German. No abstract available.
• [Secondary prevention of ischemic cardiopathy].

  Caruzzo E, Caruzzo C. Caruzzo E, et al. Cardiologia. 1995 May;40(5):347-53. Cardiologia. 1995. PMID: 8529246 Review. Italian. No abstract available.
• [Pharmacologic prevention of cardiovascular diseases--2005].

  Kancz S. Kancz S. Orv Hetil. 2005 May 15;146(20 Suppl 2):1122-31. Orv Hetil. 2005. PMID: 15945241 Review. Hungarian.
• [Secondary prevention after an acute myocardial infarct. Adrenergic beta-blockers, angiotensin-converting enzyme inhibitors and statins for everyone?].

  Morais J. Morais J. Rev Port Cardiol. 2000 Jan;19(1):99-105. Rev Port Cardiol. 2000. PMID: 10731795 Review. Portuguese. No abstract available.